Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT04578834

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Conditions: IgA Nephropathy

Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 517
Sponsor: Novartis Pharmaceuticals

Location: AZ Kidney Dise and Hypertension Ctr Glendale Arizona

Summary

The study was designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

Eligibility Criteria

Inclusion Criteria: * Male and female patients ≥ 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows: * For patients eGFR\* ≥ 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 years is required. * For patients with eGFR\* 30 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04578834). StuddyBuddy aggregates publicly available trial information.